Sinensetin

Sinensetin is a polymethoxylated flavonoid found in citrus peels that demonstrates potential as a chemotherapy adjuvant by inhibiting drug efflux pumps. This compound specifically targets P-glycoprotein and ABCG2 transporters, which may enhance cancer drug accumulation in resistant cells.

Origin & History

Sinensetin is a pentamethoxyflavone (C20H20O7) naturally found in plants such as Orthosiphon stamineus (Java tea), characterized by five methoxy groups on its flavone backbone. It is typically extracted from Java tea or synthesized through methylation of 5,6,7,3′,4′-pentahydroxyflavone using dimethyl sulfate and potassium carbonate.

Historical & Cultural Context

No information on traditional medicinal uses or historical context is documented in the available research. The compound's natural occurrence in Java tea suggests potential traditional use, but specific historical applications are not detailed.

Health Benefits

• May enhance chemotherapy effectiveness by inhibiting P-glycoprotein drug efflux pumps (IC50 = 3.9 µM in vitro studies only)
• Potential to increase cancer drug accumulation by inhibiting ABCG2 transporter (181.7% mitoxantrone increase at 10 µM in cell studies)
• Demonstrates antimicrobial activity against E. coli O157:H7 motility (100 µM in vitro)
• May improve drug bioavailability through transport protein inhibition (79.68% P-gp inhibition at 100 µM in cell models)
• Note: All benefits based solely on preliminary cell culture studies; no human clinical evidence exists

How It Works

Sinensetin inhibits P-glycoprotein drug efflux pumps with an IC50 of 3.9 µM, preventing cancer cells from expelling chemotherapy drugs. The compound also blocks ABCG2 transporter activity, increasing mitoxantrone accumulation by 181.7% at 10 µM concentrations. These mechanisms may help overcome multidrug resistance in cancer treatment by keeping therapeutic compounds inside target cells longer.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on sinensetin. All available evidence is limited to in vitro cell culture studies focusing primarily on its ability to inhibit drug efflux pumps P-glycoprotein and ABCG2 in cancer cell models.

Clinical Summary

Current evidence for sinensetin comes exclusively from in vitro cell culture studies examining its effects on drug transporter proteins. Laboratory research shows significant inhibition of P-glycoprotein (IC50 = 3.9 µM) and enhanced chemotherapy drug retention in resistant cell lines. Studies also demonstrate antimicrobial properties against various bacterial strains in controlled laboratory conditions. No human clinical trials or animal studies have been published to validate these cellular findings or establish safety profiles.

Nutritional Profile

Sinensetin is a polymethoxylated flavone (PMF) bioactive compound, not a macronutrient or conventional nutrient source. It contains no meaningful protein, fat, carbohydrate, fiber, vitamin, or mineral content in isolation. Molecular formula: C20H20O7; molecular weight: 376.37 g/mol. Structurally characterized by five methoxy groups at positions 4', 5, 6, 7, and 3' on the flavone backbone, distinguishing it from non-methylated flavones. Found primarily in citrus peel extracts (notably Citrus sinensis, Orthosiphon stamineus), with concentrations in dried Orthosiphon stamineus leaves reported at approximately 0.1–1.5 mg/g dry weight depending on extraction method and plant origin. Bioavailability is notably limited due to poor aqueous solubility (log P approximately 3.5, indicating high lipophilicity), which restricts oral absorption under standard conditions; however, its PMF structure confers greater intestinal permeability compared to non-methylated flavonoids. Existing data indicates it may improve its own and co-administered drug bioavailability through inhibition of ABCG2 transporter (181.7% mitoxantrone accumulation increase at 10 µM in cell studies) and P-glycoprotein efflux pumps (IC50 = 3.9 µM, in vitro). No established dietary reference intake or recommended daily amount exists. All quantified effects are derived from in vitro cell studies; human pharmacokinetic data remain limited.

Preparation & Dosage

No clinically studied dosage ranges exist as no human trials have been conducted. In vitro studies used concentrations of 5-100 µM for anticancer and antimicrobial effects, but these cannot be translated to human dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other flavonoids, P-glycoprotein inhibitors, ABCG2 inhibitors, Java tea compounds, pentamethoxyflavones

Safety & Interactions

Safety data for sinensetin supplementation in humans is currently unavailable due to lack of clinical studies. Theoretical drug interactions may occur with chemotherapy medications, potentially altering their pharmacokinetics and toxicity profiles unpredictably. The compound's ability to inhibit drug efflux pumps could increase both therapeutic effects and adverse reactions of co-administered medications. Pregnant and breastfeeding women should avoid sinensetin supplements due to unknown safety implications and potential interference with fetal development.